Trastuzumab deruxtecan approved to treat adults with HER2-positive cancer that’s spread or can’t be removed by surgery.

A&O Shearman, Weil, Gotshal & Manges and Norton Rose Fulbright are advising on a £1.3 billion transaction between Ageas and Bain Capital. Ageas has agreed to acquire the insurer ‘esure’ from Bain, ...